Search

Displaying results 3191 - 3200 of 10000 in total
  1. Drug

    Indalpine

    go.drugbank.com/drugs/DB08953
    ApprovedWithdrawn

    It was initially marketed by Pharmuka. … However, after the emergence of widespread concern regarding adverse effects caused by SSRIs, and reported hematological effects caused by Indalpine, it was abruptly withdrawn from the US market.

  2. Drug

    Axitinib

    go.drugbank.com/drugs/DB06626
    ApprovedInvestigational

    Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3). … [A179398] It is most commonly marketed under the name Inlyta® and is available in oral formulations.

    Synonyms: N-methyl-2-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]sulfanyl]benzamide
  3. Drug

    Methyclothiazide

    go.drugbank.com/drugs/DB00232
    ApprovedWithdrawn

    A thiazide diuretic with properties similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p825)

  4. Drug

    Remifentanil

    go.drugbank.com/drugs/DB00899
    ApprovedInvestigational

    Remifentanil (marketed by Abbott as Ultiva) is a potent ultra short-acting synthetic opioid given to patients during surgery for pain relief and adjunctive to an anaesthetic.

  5. Drug

    Etelcalcetide

    go.drugbank.com/drugs/DB12865
    ApprovedInvestigational

    Etelcalcetide was approved (trade name Parsabiv) for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis in February, 2017.

  6. Drug

    Propyphenazone

    go.drugbank.com/drugs/DB13524
    Investigational

    Propyphenazone is a non-steroidal anti-inflammatory agent with analgesic effects.[A275063, A275068]

    Categories: Analgesics, Non-Narcotic, Non COX-2 selective NSAIDS
  7. Drug

    Ivosidenib

    go.drugbank.com/drugs/DB14568
    ApprovedInvestigational

    [L46287] It was fully approved by the EMA in May 2023.[L46596] … [A248745] Ivosidenib was granted accelerated approval by the FDA in July 2018 for the treatment of relapsed of refractory acute myeloid leukemia in adults.

  8. Drug

    Deramciclane

    go.drugbank.com/drugs/DB06512
    Investigational

    Deramciclane differs from other anti anxiety medications in that it is not a benzodiazepine and so has a different structure and target.

  9. Drug

    5-methyltetrahydrofolic acid

    go.drugbank.com/drugs/DB04789
    InvestigationalNutraceutical

    It is generated by methylenetetrahydrofolate reductase from 5,10-methylenetetrahydrofolate and used to recycle homocysteine back to methionine by 5-methyltetrahydrofolate-homocysteine methyltransferases

    Mixtures: FeRiva 21-7 28-DaySynonyms: N-Methyltetrahydrofolate, N5-Methyltetrahydrofolate
  10. Drug

    PBI-1402

    go.drugbank.com/drugs/DB05480
    Experimental

    PBI-1402 appears to work on the PMN pathway, but its specific binding properties are not known. PBI-1402 has a dual therapeutic action; as a chemoprotectant and hematopoietic progenitor stimulator.